Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Atse H Huisman; Denise van den Berg; Saco de Visser; Bettina Ryll; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

doi:10.3389/fphar.2024.1490853

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Front Pharmacol. 2024 Nov 5:15:1490853. doi: 10.3389/fphar.2024.1490853. eCollection 2024.

Authors

Atse H Huisman^{1

2}, Denise van den Berg³, Saco de Visser⁴, Bettina Ryll^{5

6}, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani^{1

7}

Affiliations

¹ Department of Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands.
² Department of Health Policy, Health Insurers Netherlands, Zeist, Netherlands.
³ Treatmeds Foundation, 's-Hertogenbosch, Netherlands.
⁴ Centre for Future Affordable and Sustainable Therapy Development (FAST), The Hague, Netherlands.
⁵ Melanoma Patient Network Europe, Uppsala, Sweden.
⁶ Stockholm School of Economics Institute for Research, Stockholm, Sweden.
⁷ Medical Department, CZ Health Insurance, Tilburg, Netherlands.

No abstract available

Keywords: access; affordability and accessibility of medicines; compounding; cost-efectiveness; de-escalation; expensive drugs; precision medicine; repurposing.

Publication types

Editorial

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Part of the editorial work for this Research Topic is funded by the European Union under the Horizon Europe programme: The Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trial (PRIME-ROSE) (grant: 101104269).